Skip to Content
Global News Select

Jazz Pharmaceuticals Gets FDA Approval for Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treatment

By Dave Sebastian

 

Jazz Pharmaceuticals PLC said it has received approval from the U.S. Food and Drug Administration for Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.

Jazz said Rylaze was given an orphan drug designation for the treatment in June. It said it expects Rylaze to be commercially available in mid-July.

Write to Dave Sebastian at dave.sebastian@wsj.com

 

(END) Dow Jones Newswires

July 01, 2021 06:55 ET (10:55 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.